ALIM Alimera Sciences, Inc.

1.45
-0.01  -1%
Previous Close 1.46
Open 1.44
Price To book 0.00
Market Cap 94.05M
Shares 64,862,000
Volume 187,745
Short Ratio 1.57
Av. Daily Volume 517,330

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. Edited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT
  2. Investor Network: ALIMERA SCIENCES INC to Host Earnings Call
  3. Alimera Sciences reports 1Q loss
  4. Alimera Sciences Reports First Quarter 2017 Financial Results
  5. Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017
  6. ETFs with exposure to Alimera Sciences, Inc. : May 1, 2017
  7. Alimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO
  8. ETFs with exposure to Alimera Sciences, Inc. : April 7, 2017
  9. ETFs with exposure to Alimera Sciences, Inc. : March 27, 2017
  10. Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  11. Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  12. Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8%
  13. Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain
  14. Alimera Sciences to Present at the 29th Annual ROTH Conference
  15. Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference
  16. Edited Transcript of ALIM earnings conference call or presentation 2-Mar-17 3:00pm GMT
  17. Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results
  18. Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada